Filing Details

Accession Number:
0001144204-10-014151
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-03-17 13:00:00
Reporting Period:
2010-03-16
Filing Date:
2010-03-17
Accepted Time:
2010-03-17 16:58:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1318641 Cleveland Biolabs Inc CBLI Services-Commercial Physical & Biological Research (8731) 200077155
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1370083 V Andrei Gudkov 73 High Street
Buffalo NY 14203
Chief Scientific Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-03-16 300 $3.65 1,519,300 No 4 S Direct
Common Stock Disposition 2010-03-16 500 $3.64 1,518,800 No 4 S Direct
Common Stock Disposition 2010-03-16 800 $3.62 1,518,000 No 4 S Direct
Common Stock Disposition 2010-03-16 500 $3.60 1,517,500 No 4 S Direct
Common Stock Disposition 2010-03-16 1,100 $3.63 1,516,400 No 4 S Direct
Common Stock Disposition 2010-03-16 650 $3.59 1,515,750 No 4 S Direct
Common Stock Disposition 2010-03-16 50 $3.58 1,515,700 No 4 S Direct
Common Stock Disposition 2010-03-16 1,100 $3.57 1,514,600 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Employee Stock Options (Right to Buy) $8.36 2007-04-06 2017-04-05 37,500 37,500 Direct
Common Stock Employee Stock Options (Right to Buy) $4.00 2008-02-04 2018-02-03 137,250 174,750 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2017-04-05 37,500 37,500 Direct
2018-02-03 137,250 174,750 Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and represent approximately 0.3% of the reporting person's 1,549,600 shares held prior to adoption of the plan. The maximum sales subject to the plan in its entirety represent approximately 3.9% of the reporting person's shares held prior to adoption of the plan.